DDInter947 DDInter1055
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoniazid
Isoniazid {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stanozolol
Stanozolol {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is palliated by {v} (Compound) Levofloxacin
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Quinolones {u} (Pharmacologic Class) includes {v} (Compound) Levofloxacin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol and Stanozolol (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is palliated by Levofloxacin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) is included by Quinolones (Pharmacologic Class) and Quinolones (Pharmacologic Class) includes Levofloxacin (Compound)